Physician profile
Keisha Sinha
NPI 1538227392
$2,534.24
in general payments reported to CMS, 2019-2025
23 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $272 · 2021: $49.85 · 2022: $360 · 2023: $211 · 2024: $593 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $446.66 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $263.49 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $253.74 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Baxter Healthcare | $233.36 | 2022 | |
| Exact Sciences Corporation | $213.26 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $173.22 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $159.08 | 2019-2022 | |
| Amarin Pharma, INC. | $149.86 | 2019-2020 | |
| Glaxosmithkline, LLC. | $116.01 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.11 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $87.90 | 2024-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $69.58 | 2019-2020 | |
| Gilead Sciences, INC. | $48.33 | 2019 | |
| Mylan Specialty L.P. | $44.15 | 2024 | Yupelri |
| Arbor Pharmaceuticals, INC. | $38.74 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.19 | 2019 | |
| Allergan, INC. | $18.33 | 2019 | |
| Abbvie INC. | $18.27 | 2024 | |
| Sanofi-Aventis U.S. LLC | $17.20 | 2019 | |
| Pfizer INC. | $16.33 | 2025 | |
| Phadia US INC. | $15.13 | 2023 | Immunocap |
| Medtronic Minimed, INC. | $12.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keisha Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.